Dual immune checkpoint blockade in advanced well-differentiated neuroendocrine tumors, a phase II clinical trial
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Background Limited options result in objective responses in patients with well-differentiated neuroendocrine tumors (WD-NET). We tested the efficacy of dual immune checkpoint blockade in patients with WD-NET. Methods We planned a phase II clinical trial in patients with WD-NET who progressed within the past 12 months to standard treatments. Patients received ipilimumab 1 mg/kg every 6 weeks and nivolumab 240 mg every 2 weeks for up to 2 years. The primary endpoint was objective response rate (ORR) by RECIST v1.1. Using Simon’s 2-stage design, the study planned to accrue 56 patients. This regimen would be considered promising if ORR >15%. Results Nine patients were enrolled (6 lung, 2 pancreatic, and 1 small bowel). The Mean age was 63.7 years. Four of eight evaluable patients achieved confirmed response (ORR 50%, 95% CI: 16–84). Five of nine patients experienced immune-related toxicity. The trial closed before completing Stage 1 enrollment (9 of 20 planned patients). No formal statistical conclusion could be applied given the incomplete accrual. We observed a higher CD3 infiltration in pre-treatment tumors of patients who had achieved radiological response as compared with those of nonresponders. Conclusions The combination of ipilimumab and nivolumab in patients with WD-NET results in an observed ORR of 50% in this small clinical trial. These results are hypothesis-generating given the small sample size and premature trial closure. Clinical trial registration https://clinicaltrials.gov/study/NCT03420521 , identifier NCT03420521
Source: Frontiers in Immunology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7226005265
